Dr. Melanie Bergman, MD
Claim this profileProvidence Sacred Heart Medical Center and Children's Hospital
Studies Ovarian Tumors
Studies Fallopian Tube Cancer
6 reported clinical trials
12 drugs studied
Area of expertise
1Ovarian Tumors
Stage IV
Stage III
2Fallopian Tube Cancer
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Melanie Bergman, MD is currently running
Olvi-Vec + Chemotherapy
for Ovarian Cancer
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.
Recruiting2 awards Phase 313 criteria
ACR-368
for Ovarian Cancer
This trial tests a new drug, ACR-368, alone or with a small dose of another drug, gemcitabine, in patients whose cancers don't respond to standard treatments. A special test helps decide which treatment might work best for each patient. Gemcitabine has been used with other drugs for various cancers, including pancreatic, lung, ovarian, and breast cancers.
Recruiting1 award Phase 1 & 210 criteria
More about Melanie Bergman, MD
Clinical Trial Related2 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Melanie Bergman, MD has experience with
- Gemcitabine
- MORAb-202
- Topotecan
- Paclitaxel
- Pegylated Liposomal Doxorubicin (PLD)
- GEN-1
Breakdown of trials Melanie Bergman, MD has run
Ovarian Tumors
Fallopian Tube Cancer
Ovarian Cancer
Endometrial Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Melanie Bergman, MD specialize in?
Melanie Bergman, MD focuses on Ovarian Tumors and Fallopian Tube Cancer. In particular, much of their work with Ovarian Tumors has involved Stage IV patients, or patients who are Stage III.
Is Melanie Bergman, MD currently recruiting for clinical trials?
Yes, Melanie Bergman, MD is currently recruiting for 4 clinical trials in Spokane Washington. If you're interested in participating, you should apply.
Are there any treatments that Melanie Bergman, MD has studied deeply?
Yes, Melanie Bergman, MD has studied treatments such as Gemcitabine, MORAb-202, Topotecan.
What is the best way to schedule an appointment with Melanie Bergman, MD?
Apply for one of the trials that Melanie Bergman, MD is conducting.
What is the office address of Melanie Bergman, MD?
The office of Melanie Bergman, MD is located at: Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington 99204-2307 United States. This is the address for their practice at the Providence Sacred Heart Medical Center and Children's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.